What is Junevity?
Junevity is a biotechnology company dedicated to advancing human healthspan and addressing the root causes of age-related diseases. The company's core focus lies in pioneering cell-reprogramming therapies designed to treat conditions such as type 2 diabetes and obesity. By targeting the fundamental mechanisms of aging at a cellular level, Junevity aims to offer novel therapeutic solutions for widespread health challenges.
How much funding has Junevity raised?
Junevity has raised a total of $20M across 1 funding round:
Seed
$20M
Seed (2025): $20M with participation from Goldcrest Investments
Key Investors in Junevity
Goldcrest Investments
Goldcrest Investments is a venture capital fund specializing in private technology companies, providing capital and strategic guidance to innovative startups.
What's next for Junevity?
With the recent major strategic investment and substantial total funding, Junevity is poised for accelerated development and scaling of its innovative cell-reprogramming technologies. This enterprise-level backing suggests a strong validation of the company's scientific approach and market potential. The capital infusion is expected to fuel further research, clinical trials, and the expansion of its therapeutic pipeline, potentially bringing its treatments for type 2 diabetes and obesity closer to market.
See full Junevity company page
